January 1 2024

Holoclara Announces Business Operations Hire

PASADENA, Cal.- Holoclara announces that it has appointed Oliver Loson, Ph.D., as Vice President of Business Operations. In his new role, Loson will support Holoclara in all areas of business operations, as the Company accelerates development towards their first clinical trial.

Prior to his role at Holoclara, Oliver supported 1200 Pharma as Associate Vice President of Discovery, Strategy, and Development. Oliver played key roles in their operations and discovery research. He also led and managed the translational biology and preclinical development of three programs, two of which produced clinical candidates that were studied in two distinct multi-center Phase 1 clinical trials in patients with advanced disease.

Oliver was trained as a PhD biochemist and molecular biologist at the California Institute of Technology (Caltech). Following his doctoral work, Oliver joined Caltech’s Office of Technology Transfer and Corporate Partnerships (OTTCP). While there, Oliver managed the patent prosecution of Caltech’s chemistry and biology innovations, and negotiated licenses and other business agreements that enabled the commercialization of these innovations. He also worked with over two dozen startups to help them develop business plans and product development strategies as they prepared to launch. His patent law and patent prosecution knowledge were strengthened through his successful registration as a patent agent with the United States Patent and Trademark Office. “I’ve known Oliver since his time at Caltech. He has played an instrumental role in several organizations before Holoclara,” said CEO Andrea Choe.  “His extensive experience working with our team will be of enormous value as he takes on this expanded leadership position.”

Oliver’s diverse skillsets will allow him to support key aspects of Holoclara’s mission to bring novel, worm-derived therapies to patients in need. Oliver will help lead the launch of Holoclara’s first clinical trial for its lead development candidate, as well as supporting Holoclara’s discovery research. Oliver will also help lead Holoclara’s external research collaborations and engagement with clinical and research partners.